Physician profile
Tetsuya Takeuchi
NPI 1447550884
$21,704.54
in general payments reported to CMS, 2019-2025
8 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 83% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.80 · 2020: $12K · 2021: $6,039 · 2022: $56.23 · 2023: $196 · 2024: $1,165 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,556.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $20,209.37 | 2020-2025 | |
| Aroa Biosurgery Incorporated | $450.01 | 2022-2025 | |
| Integra Lifesciences Corporation | $301.89 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Biosense Webster, INC. | $293.48 | 2024 | Carto 3 |
| Davol INC. | $234.03 | 2023-2024 | Arista Ah Flexitip, Phasix Mesh |
| Smith+Nephew, INC. | $180.34 | 2024 | Journey II, Ri Hip Navigation, Legion Revision |
| Haemonetics Corporation | $22.77 | 2025 | Teg6s Hemostasis System |
| Astrazeneca Pharmaceuticals LP | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tetsuya Takeuchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.